Detail akcie NeoGenomics Inc online

Business Summary: NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Financial Summary: BRIEF: For the six months ended 30 June 2025, NeoGenomics, Inc. revenues increased 9% to $349.4M. Net loss increased 55% to $71M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative increase of 5% to $114M (expense), Stock-based Compensation in SGA increase of 36% to $19.2M (expense).